3 results
Approved WMOPending
Primary Objective* To assess the safety, tolerability, and efficacy (in terms of change in DAS28 [using C-ReactiveProtein (CRP)] from baseline) of JNJ-38518168 at a dose of 100 mg/day for up to 12 weekscompared to placebo in subjects with active…
Approved WMOCompleted
Primary Objective:In this pilot study, the authors aim is to investigate whether esketamine reduces the incidence of POD in elderly patientspresenting for noncardiac surgery.Secondary Objective(s):To examine whether esketamine has an effect on the…
Approved WMOCompleted
To evaluate the effect of intranasal esketamine 84 mg on cognition, and duration of cognitive effects (if present), as assessed using a computerized test battery (Cogstate®).